Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective study, researchers observed that additional rounds of intravenous corticosteroid pulse therapy led to only partial hair regrowth in some rapidly progressive alopecia areata cases, with all participants experiencing relapse, indicating limited efficacy for severe cases resistant to initial treatment.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

In this study, the 308-nm excimer lamp was reported to be a safe alternative treatment for alopecia areata, with a 41.1% overall response rate and a 50% response rate in severe cases.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This study found that home-use diphenylcyclopropenone (H-DPCP) is a cost-effective alternative to office-use for severe alopecia areata, showing similar effectiveness with reduced costs.

In this research, the authors reported that long-term treatment with the JAK1/JAK2 inhibitor baricitinib effectively maintains hair regrowth in patients with severe alopecia areata and may gradually improve outcomes for partial responders over 104 weeks, without increasing side effect incidence.

This review discusses current and emerging treatments for alopecia areata, emphasizing systemic treatments for moderate to severe cases, and reports no new clinical results.

This study reports that topical immunotherapy with SADBE and DPCP is the most effective short-term treatment for hair regrowth in children with severe alopecia areata compared to other treatments.

In this study, US-based experts reached a consensus on treating adults with severe alopecia areata, recommending oral Janus kinase inhibitors as the primary long-term therapy, while also suggesting supplemental treatments like minoxidil and corticosteroids, with a call for more research on specific patient subpopulations.

This study found that oral JAK inhibitors significantly improve hair regrowth in adults with moderate-to-severe alopecia areata compared to placebo, although they are associated with a higher risk of non-serious adverse events.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

This study reported two cases of severe multifocal alopecia areata successfully treated with a combination of topical minoxidil and intralesional platelet-rich plasma, resulting in significant hair regrowth, though further controlled trials are needed to confirm these findings.

In this study, patients with severe alopecia areata treated with baricitinib showed continued improvement in scalp hair regrowth from weeks 52 to 152, particularly among those initially responding with eyelash or eyebrow regrowth but not scalp hair, with 39% achieving substantial regrowth by week 104.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.

This study reports that yellow dots in a higher number per field of vision were the most consistent dermoscopic finding in severe cases of alopecia areata.

This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

This case report describes a 50-year-old woman with palmoplantar psoriasis who developed alopecia areata after starting tildrakizumab, suggesting a possible paradoxical reaction related to the medication.

This review examines AAS-related deaths and finds that anabolic-androgenic steroid abuse may lead to severe cardiac abnormalities, contributing to fatal arrhythmias and sudden cardiac death in young athletes and bodybuilders.

This study found that patients with alopecia areata, particularly those with severe cases, exhibit significant systemic immune dysregulation, including altered cell communication networks and epigenetic remodeling in immune cells, suggesting potential pathways for therapeutic targeting.

In this study, JAK inhibitors were reported as safe and effective treatments for moderate-to-severe chronic alopecia areata, although the appropriate duration of treatment remains uncertain, as stopping these medications often results in relapse.

This review discusses the adverse effects and societal influence of anabolic-androgenic steroid abuse, emphasizing its severe long-term health risks and calling for increased awareness and regulation; it reports no new results.

In this study, data from multiple sources found that Baricitinib significantly promoted hair regrowth and improved patient-reported outcomes in those with severe alopecia, with minimal side effects, over a 36-week period.

This review discusses multisystem inflammatory syndrome in adults (MIS-A) related to SARS-CoV2 and outlines the existing knowledge and unanswered questions, reporting no new clinical results.

This report describes the clinical presentation of Papillon-Lefèvre syndrome in two brothers and reviews the related literature, without providing new clinical outcomes.

The research observed that among Ecuadorian Andean women with polycystic ovary syndrome, classical phenotypes A and B were more prevalent and associated with higher risks of insulin resistance and metabolic disorders compared to phenotypes C and D.

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.